Van ECK Associates Corp Has $28.97 Million Stock Holdings in Sanofi $SNY

Van ECK Associates Corp decreased its position in Sanofi (NASDAQ:SNY) by 5.6% during the 3rd quarter, HoldingsChannel reports. The fund owned 613,817 shares of the company’s stock after selling 36,682 shares during the quarter. Van ECK Associates Corp’s holdings in Sanofi were worth $28,972,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of SNY. Causeway Capital Management LLC boosted its holdings in Sanofi by 16.6% during the third quarter. Causeway Capital Management LLC now owns 979,317 shares of the company’s stock worth $46,224,000 after purchasing an additional 139,678 shares during the last quarter. Bank of Montreal Can increased its position in shares of Sanofi by 9.4% in the third quarter. Bank of Montreal Can now owns 261,409 shares of the company’s stock valued at $12,339,000 after acquiring an additional 22,353 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in Sanofi by 39.0% during the third quarter. Russell Investments Group Ltd. now owns 535,527 shares of the company’s stock worth $25,277,000 after acquiring an additional 150,198 shares in the last quarter. Schroder Investment Management Group bought a new stake in Sanofi during the third quarter worth about $5,661,000. Finally, Private Advisor Group LLC boosted its position in Sanofi by 9.2% during the third quarter. Private Advisor Group LLC now owns 80,316 shares of the company’s stock valued at $3,791,000 after purchasing an additional 6,782 shares during the last quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

Wall Street Analyst Weigh In

SNY has been the topic of several recent analyst reports. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research report on Monday, December 8th. Weiss Ratings restated a “hold (c)” rating on shares of Sanofi in a report on Monday, December 29th. Bank of America lowered shares of Sanofi from a “buy” rating to a “neutral” rating in a research report on Thursday, February 12th. UBS Group reissued a “neutral” rating on shares of Sanofi in a research report on Friday, January 16th. Finally, Citigroup began coverage on shares of Sanofi in a report on Tuesday, January 27th. They issued a “neutral” rating on the stock. Five equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $62.67.

Sanofi Price Performance

NASDAQ:SNY opened at $43.94 on Thursday. The company has a market cap of $107.17 billion, a P/E ratio of 12.21, a P/E/G ratio of 1.14 and a beta of 0.45. The firm’s fifty day moving average price is $47.04 and its two-hundred day moving average price is $48.32. Sanofi has a one year low of $43.34 and a one year high of $59.17. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.09 and a quick ratio of 0.73.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.